Beyond CA125: the coming of age of ovarian cancer biomarkers. Are we there yet?
Ovarian cancer (OC) is the fourth leading cause of cancer deaths among women in the United States, despite its relatively low incidence of 50 per 100,000. Even though advances in therapy have been made, the OC fatality-to-case ratio remains exceedingly high, due to the lack of accurate tools to diagnose early-stage disease when cure is still possible. The most studied marker for OC, CA125, is only expressed by 50-60% of patients with early stage disease. Large efforts have been deployed to identify novel serum markers, yet no single marker has emerged as a serious competitor for CA125. Various groups are investing in combination approaches to increase the diagnostic value of existing markers, but many markers may still lie in under-explored areas of ovarian cancer biology, such as tumor vasculature environment and post-translational modifications (glycomics).
Sasaroli
Dimitra
D
University of Pennsylvania School of Medicine, 421 Curie Boulevard, BRBII/III, PA, USA.
Coukos
George
G
Scholler
Nathalie
N
N Engl J Med. 2005 Sep 22;353(12):1224-35
16177248
Cancer Res. 2003 Jul 1;63(13):3695-700
12839961
Endocr Rev. 2001 Apr;22(2):255-88
11294827
Mol Cancer. 2006 Oct 26;5(1):50
17067392
Proc Natl Acad Sci U S A. 2005 May 24;102(21):7677-82
15890779
Am J Obstet Gynecol. 2004 Sep;191(3):718-32
15467531
Glycobiology. 2006 Feb;16(2):132-45
16177264
Int J Cancer. 2002 Apr 10;98(5):737-40
11920644
Am J Pathol. 2004 Aug;165(2):601-8
15277233
Gynecol Oncol. 1994 Mar;52(3):301-5
7512519
Clin Cancer Res. 2008 Nov 15;14(22):7574; author reply 7577-9
18948386
Biomark Med. 2007 Dec;1(4):513-23
20477371
Clin Chem. 2008 Oct;54(10):1600-7
18687738
Int J Gynecol Cancer. 2006 Jan-Feb;16 Suppl 1:54-9
16515568
J Natl Cancer Inst. 1999 Sep 1;91(17):1459-67
10469746
Science. 2000 Aug 18;289(5482):1197-202
10947988
J Proteome Res. 2007 Jul;6(7):2509-17
17547437
Cancer Lett. 2007 Apr 28;249(1):14-7
17320281
Int J Cancer. 1996 Aug 22;69(4):283-9
8797869
Lancet Oncol. 2009 Apr;10(4):327-40
19282241
Nature. 2001 May 17;411(6835):375-9
11357145
J Clin Oncol. 2005 Aug 20;23(24):5588-96
16110018
Hematol Oncol Clin North Am. 2003 Aug;17(4):989-1005, ix
12959188
Biotechniques. 2001 Mar;30(3):670-5
11252802
Mol Immunol. 1997 Jan;34(1):9-20
9182872
J Clin Endocrinol Metab. 2002 Feb;87(2):816-24
11836327
Eur J Obstet Gynecol Reprod Biol. 1997 Dec;75(2):205-6
9447374
J Clin Invest. 1981 Nov;68(5):1331-7
7028788
Clin Cancer Res. 2007 Dec 1;13(23):6984-92
18056174
Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):2117-24
16609024
Nature. 2007 Dec 20;450(7173):1235-9
18097410
Cancer Res. 2007 Feb 15;67(4):1757-68
17308118
J Proteome Res. 2008 Jan;7(1):319-27
18047267
Anticancer Res. 1999 Mar-Apr;19(2B):1401-5
10365113
Gynecol Oncol. 2008 Sep;110(3):374-82
18584856
Br J Cancer. 2002 Jul 29;87(3):339-43
12177805
Am J Obstet Gynecol. 1991 Nov;165(5 Pt 1):1356-62
1957862
Cancer Res. 1984 Mar;44(3):1048-53
6198078
Am J Surg Pathol. 2006 Feb;30(2):230-6
16434898
Expert Opin Ther Targets. 2005 Dec;9(6):1203-16
16300471
Clin Cancer Res. 1997 Apr;3(4):605-11
9815727
Dis Markers. 2007;23(5-6):419-31
18057525
Mol Cell Proteomics. 2004 Apr;3(4):355-66
14764655
Cancer Res. 2003 May 1;63(9):2223-7
12727843
J Clin Oncol. 2008 Nov 10;26(32):5284-93
18854563
J Biol Chem. 2004 Mar 5;279(10):9190-8
14676194
Anticancer Res. 2000 Nov-Dec;20(6D):5109-12
11326678
J Exp Med. 1998 Apr 20;187(8):1163-7
9547328
Mol Cell Proteomics. 2009 May;8(5):995-1005
19196707
Gynecol Oncol. 2008 Feb;108(2):402-8
18061248
Int J Cancer. 1997 May 16;71(4):638-44
9178820
Clin Med Res. 2007 Mar;5(1):35-44
17456833
Nat Immunol. 2008 Nov;9(11):1225-35
18820683
Gynecol Oncol. 2005 May;97(2):476-82
15863147
N Engl J Med. 1983 Oct 13;309(15):883-7
6310399
J Immunother. 2000 Jul-Aug;23(4):473-9
10916757
Nat Rev Cancer. 2004 Nov;4(11):876-90
15516960
J Clin Oncol. 2005 Nov 1;23(31):7919-26
16258091
Gynecol Oncol. 2005 Nov;99(2):267-77
16061277
Gynecol Oncol. 2004 Oct;95(1):9-15
15385104
Nature. 2008 Apr 3;452(7187):571-9
18385731
J Immunol. 2002 Jul 15;169(2):1102-9
12097419
Int J Cancer. 2009 Feb 15;124(4):919-23
19035463
Gene. 2007 Sep 15;399(2):137-43
17560052
Clin Chem. 2008 Mar;54(3):582-9
18171715
Crit Rev Biochem Mol Biol. 1997;32(1):1-100
9063619
Fertil Steril. 2001 Jun;75(6):1218-21
11384653
Arch Biochem Biophys. 2004 Jun 15;426(2):122-31
15158662
Hum Pathol. 2005 Jan;36(1):44-50
15712181
Am J Obstet Gynecol. 1991 Apr;164(4):1038-42; discussion 1042-3
2014824
Lancet Oncol. 2008 Nov;9(11):1076-85
19012856
PLoS One. 2007 Dec 05;2(12):e1281
18060075
Proc Natl Acad Sci U S A. 2007 Oct 30;104(44):17494-9
17954908
Cancer Res. 2004 Nov 1;64(21):7857-66
15520192
Arthritis Rheum. 2006 Nov;54(11):3433-40
17075835
N Engl J Med. 1993 Nov 18;329(21):1539-42
8413476
Am J Obstet Gynecol. 2008 Sep;199(3):215-23
18468571
Gynecol Oncol. 2006 Aug;102(2):244-51
16434085
Clin Cancer Res. 2006 Jan 15;12(2):447-53
16428485
Clin Cancer Res. 2008 Feb 15;14(4):1065-72
18258665
J Biol Chem. 2001 Jul 20;276(29):27371-5
11369781
Cancer Res. 2006 Jan 15;66(2):1181-90
16424057
Gynecol Oncol. 2006 Dec;103(3):1077-82
16904167
Cancer Lett. 2007 Oct 8;255(2):263-74
17560019
Mol Cell Endocrinol. 2001 Jun 30;180(1-2):73-7
11451574
JAMA. 2002 Apr 3;287(13):1671-9
11926891
Cancer Lett. 2007 Mar 8;247(1):130-6
16677756
Cancer. 1994 Apr 1;73(7):1855-8
8137210
Cell. 2007 Aug 10;130(3):395-8
17693247
Gene. 1999 Oct 1;238(2):375-85
10570965
Int J Gynecol Pathol. 2008 Jan;27(1):1-9
18156967
Clin Cancer Res. 2002 Oct;8(10):3193-7
12374688
J Transl Med. 2008 Jul 24;6:41
18652693
Cancer Res. 2005 Dec 1;65(23):10794-800
16322225
CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96
18287387
J Immunol Methods. 2006 Dec 20;317(1-2):132-43
17113097
J Clin Oncol. 2002 Mar 1;20(5):1260-8
11870168
Proteomics. 2007 Nov;7(22):4045-52
17952875
Eur J Cancer. 2005 Mar;41(4):549-54
15737559
Science. 2006 Aug 4;313(5787):670-3
16888140
Gynecol Oncol. 2006 Jan;100(1):20-6
16188302
J Virol Methods. 1998 Jul;73(1):99-107
9705181
Clin Cancer Res. 2006 Jan 15;12(2):323-7
16428467
Gynecol Oncol. 2008 May;109(2):168-73
18342932
Lancet. 2002 Jul 13;360(9327):170; author reply 170-1
12126845
Lancet. 2003 Nov 15;362(9396):1612-6
14630441
JAMA. 1998 Aug 26;280(8):719-23
9728644
Br J Cancer. 2006 Mar 27;94(6):814-9
16495917
Proc Natl Acad Sci U S A. 1999 Sep 28;96(20):11531-6
10500211
J Natl Cancer Inst. 1996 Nov 20;88(22):1652-8
8931609
Glycobiology. 2007 Dec;17(12):1344-56
17884841
Int J Gynecol Cancer. 2002 Jan-Feb;12(1):86-91
11860541
Proteomics. 2008 Aug;8(16):3284-93
18646009
J Clin Oncol. 2007 Sep 1;25(25):3985-90
17761984
Int J Gynecol Cancer. 2005 Nov-Dec;15 Suppl 3:274-81
16343244
Cancer Sci. 2008 Feb;99(2):432-40
18271942
Science. 1992 Dec 11;258(5089):1798-801
1281554
Gynecol Oncol. 2009 Jan;112(1):185-91
18954898
Clin Cancer Res. 2008 Nov 15;14(22):7574; author reply 7577-9
18948385
J Clin Oncol. 2007 Mar 1;25(7):852-61
17327606
J Pathol. 2007 Jan;211(1):26-35
17117391
Mol Cell Proteomics. 2002 Mar;1(3):197-203
12096119
Cancer Lett. 2007 Apr 28;249(1):61-79
17275179
Clin Cancer Res. 2007 Mar 1;13(5):1571-5
17332303
J Clin Invest. 1992 Mar;89(3):1021-31
1347295
Proc Natl Acad Sci U S A. 1996 Jan 9;93(1):136-40
8552591
Cancer Epidemiol Biomarkers Prev. 2005 Apr;14(4):981-7
15824174
Cancer. 2002 Aug 1;95(3):506-12
12209742
J Proteome Res. 2007 Sep;6(9):3558-65
17696519
Ann Oncol. 2007 Feb;18(2):269-74
17065588
Biomaterials. 1990 Nov;11(9):615-8
1708683
J Clin Oncol. 2003 May 15;21(10 Suppl):200s-205s
12743135
Gynecol Oncol. 1992 Feb;44(2):147-54
1312052
Cancer. 2000 Nov 15;89(10):2068-75
11066047
Clin Cancer Res. 2004 May 15;10(10):3474-8
15161704
Cancer. 1996 Nov 15;78(10):2146-52
8918407
Int J Cancer. 1994 Apr 1;57(1):90-7
8150545
Br J Cancer. 2007 Jan 29;96(2):362-72
17242704
Int J Cancer. 2003 Nov 10;107(3):359-64
14506734